ESTRO 2024 - Abstract Book

S5990

RTT - Treatment planning, OAR and target definitions

ESTRO 2024

Fig 2

Conclusion:

MRL focal boost to GTV region of the prostate was found to have a favourable acute toxicity profile compared to HDR focal boost at 1 month following completion of treatment with faster recovery to baseline. This appeared to be mirrored in the QOL scores. A larger sample size/longer follow up may confirm these preliminary findings translate into differences in late toxicity/QOL. Analysis of factors such as organs-at-risk dosimetry, amongst others, may allow better understanding of their influence on toxicity and QOL.

Keywords: HDR prostate, MR-Linac, EPIC

1917

Digital Poster

multimodal imaging in protontherapy: accuracy in contouring of organs at risk in skull base chordoma

Luca Anemoni 1 , Sara Imparato 2 , Alberto Iannalfi 3 , Giulia Riva 3 , Lucia Pia Ciccone 3 , Ester Orlandi 3 , Lorenzo Preda 4,5 , Chiara Paganelli 6 , Letizia Morelli 6 , Sara Tampellini 1 , Maria Elena Piazzolla 1 1 National Center for Oncological Hadrontherapy (Fondazione CNAO), Radiation Therapy Technologist Unit, Pavia, Italy. 2 National Center for Oncological Hadrontherapy (Fondazione CNAO), Department of Radiology, Pavia, Italy. 3 National Center for Oncological Hadrontherapy (Fondazione CNAO), Clinical Department, Pavia, Italy. 4 IRCCS Policlinico San Matteo, Department of Radiology, Pavia, Italy. 5 University of Pavia, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, Pavia, Italy. 6 Politecnico di Milano, Department of Electronics, Information and Bioengineering, Milano, Italy